Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease.

Autor:	Price DL; Neuropore Therapies, Inc., San Diego, CA, USA., Khan A; Neuropore Therapies, Inc., San Diego, CA, USA., Angers R; UCB Biopharma SPRL, Braine l'Alleud, Belgium., Cardenas A; UCB Biopharma SPRL, Braine l'Alleud, Belgium., Prato MK; UCB Biopharma SPRL, Braine l'Alleud, Belgium., Bani M; UCB Biopharma SPRL, Braine l'Alleud, Belgium., Bonhaus DW; Neuropore Therapies, Inc., San Diego, CA, USA., Citron M; UCB Biopharma SPRL, Braine l'Alleud, Belgium. Martin.Citron@ucb.com., Biere AL; UCB Biopharma SPRL, Braine l'Alleud, Belgium.
Jazyk:	angličtina
Zdroj:	NPJ Parkinson's disease [NPJ Parkinsons Dis] 2024 Mar 14; Vol. 10 (1), pp. 60. Date of Electronic Publication: 2024 Mar 14.
DOI:	10.1038/s41531-024-00658-6
Databáze:	MEDLINE
Externí odkaz:	Full text from SpringerLink